Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464948 | 0.86 | ESR1 (0.46) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL5950262 | 0.78 | ESR1 (0.65) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL15477961 | 0.78 | ESR1 (0.65) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL3600589 | 0.77 | KMT2A (0.44) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL21294252 | 0.77 | ALDH1A1 (0.63) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL126545 | 0.77 | AKR1C3 (0.69) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL6770445 | 0.77 | KMT2A (0.49) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL3600592 | 0.77 | KMT2A (0.44) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL126544 | 0.77 | AKR1C3 (0.69) | KMT2AMEN1MAPTLMNAS1PR4 | |
| SCHEMBL3604985 | 0.77 | KMT2A (0.44) | KMT2AMEN1MAPTLMNAS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-11479563-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| CN-108602770-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2022-02-08 | — | — | CN | disclosed |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0350069-B1 | METHOD FOR OXIDIZING UNSATURATED AROMATIC COMPOUNDS | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0513761-A2 | Bisphosphonate squalene synthetase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| US-5157027-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-4967009-A | REACTING UNSATURATED AROMATIC COMPOUNDS WITH AROMATIC IODOSYL COMPOUNDS TO YIELD AROMATIC ALDEHYDES OR KETONES | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0350069-A2 | Method for oxidizing unsaturated aromatic compounds | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | KMT2A 15/4885MEN1 710/4885MAPT 4549/4885 |
| US-11479563-B2 | Biphenyl compound or salt thereof | BMI1, KDM1B, KDM1A | KMT2A 16/4885MEN1 653/4885MAPT 1562/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | KMT2A 29/4885MEN1 312/4885MAPT 3740/4885 |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | KMT2A 15/4885MEN1 710/4885MAPT 4549/4885 |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, KDM1A, HDAC1 | KMT2A 14/4885MEN1 1533/4885MAPT 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.